NICE advises on use of erlotinib in NSCLC

New guidance from NICE provides recommendations on the use of erlotinib in the treatment of non-small cell lung cancer (NSCLC).

According to the new guidance erlotinib should be used as an alternative to docetaxel for patients with NSCLC for whom one chemotherapy regimen has already failed. However, NICE specifies that erlotinib should only be used as an alternative to docetaxel when the manufacturer provides the drug at the same overall cost as docetaxel.

Erlotinib is not recommended for people who have not responded to two prior chemotherapy regimens, including docetaxel or for those with locally advanced or metastatic NSCLC who cannot take docetaxel and who have not responded to one chemotherapy regimen.

A summary of the new guidance is available at www.mims.co.uk.  To read the full guidance visit the NICE website.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more